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Seung-Hwan Lee 1,2,5, Janice M. Zabolotny 1,5, Hu Huang 1,3, Hyon Lee 4, Young-Bum Kim 1,*
ABSTRACT
Background: Insulin, a pleotrophic hormone, has diverse effects in the body. Recent work has highlighted the important role of insulin’s action in
the nervous system on glucose and energy homeostasis, memory, and mood.
Scope of review: Here we review experimental and clinical work that has broadened the understanding of insulin’s diverse functions in the
central and peripheral nervous systems, including glucose and body weight homeostasis, memory and mood, with particular emphasis on
intranasal insulin.
Major conclusions: Implications for the treatment of obesity, type 2 diabetes, dementia, and mood disorders are discussed in the context of
brain insulin action. Intranasal insulin may have potential in the treatment of central nervous system-related metabolic disorders.
 2016 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
A fundamental metabolic action of insulin is to control blood glucose
concentration by stimulating glucose transport into muscle and adi-
pose tissue, and inhibiting hepatic glucose output [1]. It is now clear
that the brain is recognized as an insulin-sensitive organ that is
responsible for physiologic changes in altered metabolic disorders
such as obesity and type 2 diabetes [2,3]. Insulin’s actions are trig-
gered by binding to its cell-surface receptor, which is present in
virtually all mammalian cells [4]. In the brain, the insulin receptor is
broadly expressed in regions including the hypothalamus, hippo-
campus, and cerebral cortex, all of which are involved in the metabolic
control of insulin action, including feeding behavior, body weight
homeostasis, neuronal development and cognitive function [3,5]. In-
sulin also plays important roles in neuronal circuitry formation, syn-
aptic maintenance, neuronal survival, dendritic arborization, as well
as learning and memory [6]. In this article, we review experimental
and clinical studies that have demonstrated a new function of insulin
in metabolism, memory, and mood. We also highlight emerging evi-
dence that delivery of insulin to the central nervous system (CNS) via
intranasal administration affects CNS-related metabolic disorders that
are linked to impaired insulin action.
2. INSULIN ACTION IN THE BRAIN
2.1. Brain is an insulin-responsive organ
Crucial experimental evidence showing that the brain-speciﬁc deletion
of the insulin receptor in mice leads to obesity, hyperphagia, and
systemic insulin resistance clearly demonstrates the important func-
tion of brain insulin signaling in regulating metabolic homeostasis [7].
Emerging data also reveal that brain insulin signaling plays a pivotal
role in regulating peripheral metabolism via the modulation of auto-
nomic nervous system outﬂow to peripheral tissues [8,9]. For example,
intracerebroventricular infusion of insulin in the murine brain sup-
presses hepatic glucose production (HGP) independent of circulating
insulin and glucose levels, and these effects were abolished by
inactivation of the insulin receptor in the brain [8]. Furthermore, acti-
vation of hypothalamic insulin signaling inhibited lipolysis and stimu-
lated de novo lipogenesis by dampening sympathetic nervous system
outﬂow to adipose tissue, whereas mice lacking the neuronal insulin
receptor showed unrestrained lipolysis and decreased de novo lipo-
genesis in adipose tissue, highlighting the functional link of insulin
signaling in the axis of the brain and periphery [9]. Thus, these pe-
ripheral metabolic responses driven by brain insulin signaling could be
a decisive indicator for assessing brain insulin resistant states. Proving
this issue in humans, however, is technically beyond the scope of
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reach. On the other hand, by applying insulin intranasally to the human
brain, the impacts of central insulin action on whole body metabolism
can be evaluated.
In addition to these metabolic roles of the brain insulin receptor, a
recent study further demonstrated that insulin resistance in brain in-
duces dopaminergic dysfunction leading to anxiety and behavioral
disorders [10], indicating a new role for insulin signaling in neuronal
regulation. Along with this, a study with mice lacking brain insulin
receptor substrate 2 (IRS2), one of the major downstream signaling
pathways for the insulin receptor, suggests a potential role of IRS2 in
the regulation of hippocampal synaptic function and plasticity in mice,
which could be mediated via the N-methyl-D-aspartate (NMDA) re-
ceptor and the phosphoinositide 3-kinase (PI3K) signaling pathway
[11]. It is therefore likely that defective insulin signaling in the brain is
one of the key features in the pathogenesis of insulin resistance that is
found in obesity, type 2 diabetes, memory impairement, cognitive
dysfunction, and mood disorders (Table 1) [3,12].
2.2. Transport of endogenous insulin across the blood brain barrier
To gain access to its receptor in the CNS, insulin produced by
pancreatic beta-cells is transported across the blood brain barrier
(BBB) [13,14]. The BBB is composed of specialized capillary endo-
thelial cells that are interconnected with tight junctions, which are
impermeable to toxins, bacteria, viruses, and most substances in the
blood (cells/proteins). The cells composing the BBB are unique in that
the cell membranes are exposed to the bloodstream and the CNS,
allowing integration of signals from the periphery and the brain [6].
The transport of insulin from the bloodstream across the BBB is
Table 1 e Animal models of CNS insulin receptor deﬁciency.
CNS function IR deﬁcient model Phenotype Observations Refs
Metabolism Mouse IR knockout in nestin
expressing neurons
Weight Increased food intake in female NIRKO (brain-speciﬁc insulin
receptor deﬁcient) mice. Development of diet-sensitive obesity with
increases in body fat and mild insulin resistance in both male and
female mice.
[7]
Rat hypothalamic IR
antisense knockdown
Weight Rapid onset of hyperphagia, increased fat mass, and impaired
hepatic insulin action. No signiﬁcant change in body weight.
[38]
Rat hypothalamic IR
antisense knockdown
Weight Increased body weight and fat mass.
No changes in glucose tolerance and glucoseestimulated insulin
release.
[39]
Mouse IR knockout in tyrosine
hydroxylase expressing neurons
Weight Increased body weight, fat mass, and hyperphagia.
Altered response to cocaine under food-restricted conditions.
[138]
Rat hypothalamic IR
antisense knockdown
Glucose homeostasis Impaired ability of circulating insulin to inhibit glucose production. [8]
Mouse IR knockout in nestin
expressing neurons
Glucose homeostasis Defective counterregulatory response to hypoglycemia [139]
Mouse IR knockout in POMC
expressing neurons
Glucose homeostasis Unaltered energy and glucose homeostasis. [41]
Mouse IR knockout in AgRP
expressing neurons
Glucose homeostasis Unaltered energy homeostasis. Impaired insulin-induced
suppression of hepatic glucose production. Reduced insulin-
stimulated IL-6 expression in the liver.
[41]
Knockin IRs in AgRP or POMC
neuron on hypothalamic deﬁciency
of insulin receptors (L1 mouse)
Glucose homeostasis Restoration of insulin action in AgRP neurons and normalized insulin
suppression of HGP.
Restoration of insulin action in POMC neurons and increased HGP.
Increased energy expenditure and locomotor activity by POMC-
speciﬁc IR knock-in.
[50]
Mouse IR knockout in nestin
expressing neurons
Glucose homeostasis Glycemia-dependent impairment in the sympathoadrenal response
to hypoglycemia due to deletion of IR in the brain.
[140]
Rat VMH IR antisense knockdown Glucose homeostasis Glucose intolerance and islet dysfunction.
No effect on weight.
[40]
Mouse IR knockout in nestin
expressing neurons
Lipid homeostasis Unrepressed lipolysis and reduced de novo lipogenesis in white
adipose tissue.
[9]
Mouse IR knockout in nestin
expressing neurons
Hyperthermia Defective IGF-1 mediated hyperthermic response. [141]
Memory Mouse IR knockout in nestin
expressing neurons
Neuronal function No alteration in neuronal proliferation/survival, memory, or basal
brain glucose metabolism.
[114]
Mouse IR kinase þ/ Behavioral function Impaired recognition of familiarized objects; poor performance on
both short-term (1 h) and long-term (24 h) memory tests in IR
kinase þ/ mice.
[117]
Mouse IR knockout in nestin
expressing neurons in Tg2676 AD
mouse model
Neuronal function Protection from premature death in the presence of decreased Ab
accumulation speciﬁcally in the hippocampus formation in
nIGF-1R(/)Tg2576 mice with no inﬂuence on lethality of Tg2576
mice.
[115]
Mouse IR knockout in nestin
expressing neurons in Tg2676 AD
mouse model
Neuronal function Decreased Ab burden without rescue from premature mortality of
Tg2576 mice.
[142]
Mood Rat hypothalamic IR
antisense knockdown
Behavioral function Increase in immobility time with corresponding decrease in active
behaviors and increases in anxiety-like behaviors
[134]
Mouse IR knockout in nestin
expressing neurons
Behavioral function Development of age-related anxiety and depression-like behavioral
changes that were reversed with antidepressant treatment
[10]
AD, Alzheimer’s disease; AgRP, agouti-related peptide; CNS, central nervous system; HGP, hepatic glucose production; IGF-1, insulin-like growth factor-1; IR, insulin receptor; POMC,
proopiomelanocortin; VMH, ventromedial hypothalamus.
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accomplished via a saturable transport system [13]. Insulin crosses
the BBB into the hypothalamus, pons-medulla, hippocampus, stria-
tum, parietal cortex and frontal cortex but not into the midbrain,
thalamus, and occipital cortex [14]. Numerous animal studies have
demonstrated that impairment in the insulin transport system of the
BBB is found in obesity-associated insulin resistance as well as
various physiological extremes, including starvation, hyperglycemia,
activation of the immune system, and hibernation, suggesting an
important function of the BBB in maintaining normal metabolic ho-
meostasis [15]. In this regard, a recent study with human subjects
further suggests a signiﬁcant role for the insulin transport system in
brain insulin action, as revealed by ﬁndings that cerebrospinal ﬂuid
(CSF) and circulating insulin levels are closely correlated with whole-
body insulin sensitivity in insulin-sensitive humans but not in insulin-
resistant humans [16]. Furthermore, another human study indicated
that cerebrocortical activity in response to hyperinsulinemia, assessed
by magnetoencephalography, was impaired in obese insulin-resistant
humans who had an IRS1 Gly972Arg polymorphism [17], a candidate
gene for developing type 2 diabetes. This effect could be due to an
impaired insulin transport system in the BBB of humans with obesity.
However, identiﬁcation of the molecular mechanisms for this phe-
nomenon remains to be elucidated and will be an important subject of
future studies. Nevertheless, it is likely that a defective insulin
transport system in the BBB is linked to peripheral insulin resistance
may contribute to the pathogenesis of metabolic disorders such as
obesity and type 2 diabetes.
Of note, some evidence indicates that insulin is also synthesized in the
brain. Detection of C-peptide immunoreactivity in the neurons of hu-
man CNS [18,19] and proinsulin or preproinsulin mRNA in animals and
cell culture systems [20,21] suggests the possibility of local insulin
synthesis in the brain. However, the source of CNS insulin, whether it is
peripheral, central or both, is still debated and more evidence is
needed to conﬁrm this in humans.
2.3. Intranasal administration delivers insulin into the CNS
Several regions of the brain lack a blood brain barrier, including the
olfactory bulb, which has been exploited therapeutically to deliver in-
sulin into the CNS directly from the periphery via the nasal epithelium.
In humans, intranasal delivery of insulin allows direct access to the
brain without affecting peripheral glucose or insulin levels [22]. Two
possible routes have been proposed: 1) an intraneuronal pathway that
involves the internalization of the peptide into olfactory neurons, fol-
lowed by axonal transport into the brain parenchyma and 2) an
extraneuronal pathway in which the peptides diffuse into the sub-
arachnoid space by passing through patent intercellular clefts in the
olfactory epithelium [23e25]. Although the efﬁciency of intranasal
delivery by insufﬂations seems to be restricted, it is considered a novel
and promising strategy for the treatment of diseases with CNS
involvement [26]. The effect of intranasal insulin on hyperglycemia,
obesity, memory and cognitive impairment has been widely tested as
described in Table 2.
3. CNS INSULIN ACTION AND METABOLISM
“We have treated ﬁfteen patients in the hospital over periods of time varying
from two weeks to two months and have been able to keep them relatively
sugar free by the intranasal method. Whether this method of administration
is practical in the treatment of diabetic patients further observations alone
can determine. The treatment may prove too expensive to be practical and
we may also discover great variations in absorption in different patients. The
fact that insulin under certain conditions can be absorbed from mucous
membranes is, however, of more than academic interest.” (Major RH, 1935)
[27]
3.1. Brain insulin resistance accompanies obesity and diabetes
Several lines of evidence suggest the existence of abnormal brain
insulin action in diabetes and obesity. Abnormalities in CNS insulin
action reﬂect defects in insulin transport across the BBB or impaired
insulin signaling in insulin receptor-expressing cells of the CNS, or a
combination of the two. CNS insulin levels are signiﬁcantly reduced in
high-fat diet-induced obese dogs [28] and genetically obese rats [29].
A down regulation of brain capillary insulin receptors could be a po-
tential mechanism for these effects [30]. Consistent with this, insulin-
resistant human subjects displayed a lower CSF/serum insulin ratio
compared to insulin-sensitive subjects, suggesting insulin-resistance
impairs insulin transport across the BBB in humans [16]. In the pe-
riphery, an impairment of the proximal components of the insulin
signaling pathways, IR/PI3K/Akt, is thought to be a molecular mech-
anism responsible for insulin resistance in animals and humans [4,31].
Similar observations were found in the hypothalamus of genetically
obese and diet-induced obese insulin-resistant rats [32,33], sug-
gesting an essential role for insulin signaling in the CNS in metabolic
disorders. Of note, given that insulin resistance is a pathological
condition in which cells fail to respond to the metabolic actions of
insulin, brain insulin-responsive physiological outcomes, including
feeding behavior, hepatic glucose production, fat mass mobilization,
hypothermia, responsiveness to hypoglycemia, and neuronal function,
can be used as indicators of alterations in the brain insulin-resistant
state.
3.2. Hypothalamic insulin action in glucose and energy
homeostasis
Pioneering experiments evaluating the central effect of insulin in
regulating glucose metabolism and energy homeostasis were con-
ducted by Porte and colleagues more than 40 years ago. Intra-
cerebroventricular injection of insulin increased pancreatic insulin
secretion in dogs [34] and decreased food intake and body weight in
baboons [35]. Likewise, intranasal insulin also decreased circulating
glucose concentrations in dogs [36] and rhesus monkeys [37]. The
knockout of the insulin receptor in the murine brain following the
introduction of cre-loxP recombinant engineering, has demonstrated
the role of central insulin resistance in energy homeostasis, fuel
metabolism, and reproduction. Brain-speciﬁc insulin receptor inacti-
vation did not affect brain development or neuronal survival but caused
diet-sensitive obesity with increases in body fat [7].
The hypothalamus is an important mediator of energy balance, food
intake, and glucose homeostasis within the brain. Rodents with se-
lective hypothalamic insulin resistance, achieved by an intra-
hypothalamic injection of antisense oligodeoxynucleotides speciﬁc for
the insulin receptor, failed to suppress hepatic glucose production and
food intake, suggesting that the hypothalamic insulin resistance plays
a critical role in insulin’s effects on energy and glucose metabolism
[8,38]. Selective knockdown of the insulin receptor in the rat hypo-
thalamus also increases body weight and adiposity [39]. More recently,
studies showed that chronic reduction of the insulin receptor in the
ventromedial hypothalamus (VMH) of rats led to glucose intolerance
due to islet dysfunction, though body adiposity was not affected,
suggesting that VMH insulin signaling may regulate glucose but not
energy homeostasis [40]. Metabolic observations from animal models
lacking or inhibiting the insulin receptor in the brain are summarized in
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Table 2 e Intranasal insulin treatment outcomes.
CNS function Clinical subjects Intranasal insulin Phenotype Treatment outcomes Refs
Metabolism Diabetics e fed 1 or 2 doses (100 IU) Glycemia Lowered blood glucose in all patients. [27]
Diabetics e fasted Single dose (25 IU) Rare occurrence of hypoglycemic shock via intranasal
method.
Normal subjects Single dose (20e60
IU)
Glycemia Induced hypoglycemia. [59]
Insulin-dependent
diabetics
Single dose Improved postprandial hyperglycemia.
Healthy subjects Single dose (0.5 IU/kg) Glycemia Reduced blood glucose concentrations with insulin-
deoxycholate aerosol.
[60]
Type 1 and 2 diabetics
Normal subjects Single dose (1 IU/kg) Glycemia Lowered fasting and postprandial glucose levels. [61]
Type 1 diabetic men
and women
3 months Improved long-term glycemic control.
Non-obese type 2
diabetic men and
women
Single dose (30 IU) Glycemia Hypoglycemic effect persisted for less than 2 h in the
fasting state. Reduction in postprandial hyperglycemia
persisted for 4 h.
[63]
Type 1 diabetic men
and women
3 doses (up to 120 IU
each) t.i.d. at meals
Glycemia Controlled glycemia in half of patients with intranasal
insulin when combined with daily ultralente insulin.
[62]
Fasted normal men Single dose (1 IU/kg) Glycemia Blood glucose concentration decreased at 45 min. [64]
Type 2 diabetics Single dose (60 or 120
IU)
Glycemia No hypoglycemia; effective at reducing post-prandial
hyperglycemia.
[65]
Type 2 diabetics with
oral drug failure
4 months (up to
240 IU/day, t.i.d.)
Glycemia Similar diabetes control to conventional treatment with
twice daily NPH insulin.
[66]
Normal weight men or
women
single dose (160 IU) Glycemia Increased plasma insulin and decreased plasma
glucose.
[57]
Increased fMRI activity in the hypothalamus correlated
with increased HOMA-IR at 30 min post treatment.
Decreased fMRI activity in the putamen, right insula
and orbitofrontal cortex correlated with decreased
HOMA-IR at 120 min post treatment.
Type 2 diabetics single dose (15 IU) Glycemia No improvement in post-prandial hyperglycemia. [67]
Insulin-dependent
diabetics
1 month (at
mealtimes, various
doses)
Glycemia Metabolic control deteriorated compared to
subcutaneous insulin therapy.
[68]
Healthy subjects 1.5 h (20 IU, every
15 min)
Glycemia No effect on glycemia and insulin levels. [69]
Normal weight men single dose (160 IU) Glycemia No effect on postprandial glucose concentrations. [70]
Normal weight men or
women
single dose (160 IU) Weight Decreased food intake in men, not in women. [72]
Normal weight pre and
post menopausal
women
single dose (160 IU) Weight No effect on food intake. [73]
Obese men 8 weeks (40 IU, q.i.d.) Weight No effect on weight or body fat. [80]
Normal weight women single dose (160 IU) Weight Decreased appetite, food intake and rated palatability
after postprandial insulin.
[75]
Normal weight men single dose (40 IU) Weight Increased brain ATP and phosphocreatine. [76]
Change in cerebral energy content correlated inversely
with subsequent calorie intake.
Normal weight men or
women
single dose (160 IU) Weight Reduced food image-cued activity in the fusiform
gyrus, hippocampus, and temporal superior and
frontal middle cortex.
[77]
No effect on nonfood image-cued brain activity.
Normal weight women single dose (160 IU) Weight Modulation of hypothalamus and orbitofrontal cortex
activity by insulin.
[78]
Correlation of prefrontal cortex and anterior cingulate
cortex insulin response with BMI.
Normal weight men or
women
8 weeks (40 IU, q.i.d.) Weight Reduced weight and body fat in men. [74]
No effect in women.
Normal weight men or
women
single dose (160 IU) Lipolysis Suppressed systemic FFA levels without affecting
lipolytic proteins in subcutaneous adipose tissue.
[143]
Normal weight men single dose (160 IU) Thermogenesis Increased postprandial diet-induced thermogenesis. [70]
Lean and obese men two days (160 IU per
day)
Insulin sensitivity Improved peripheral insulin sensitivity in lean but not
obese men.
[71]
Lean and type 2
diabetic men or
women
1 week (160 IU per
day)
Hepatic fat and
energy
metabolism
Rapid improvement of hepatic energy metabolism
without affecting hepatic insulin sensitivity in healthy
humans, independent of peripheral insulinemia.
Blunted response in patients with type 2 diabetes.
[144]
Lean and obese or
overweight men
single dose (160 IU) Cerebral blood
ﬂow
Selectively impaired brain insulin action in the
prefrontal cortex in overweight and obese adults and in
the hypothalamus in participants with high visceral
adipose tissue.
[79]
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Table 1. These studies led scientists to map the neuronal circuitry and
molecular mechanisms involved in hypothalamic insulin action on
energy homeostasis and glucose tolerance.
3.3. Neuronal circuitry mediating hypothalamic insulin action on
glucose and energy homeostasis
Several recent studies have focused on elucidating the neuronal
circuitry that underlies insulin action on body weight and glucose
homeostasis in the hypothalamus. The arcuate nucleus of the
mediobasal hypothalamus, adjacent to the third ventricle and the
median eminence, contains important populations of neurons that
respond to afferent signals from hormones and nutrients. Insulin re-
ceptors are highly expressed in neurons expressing proopiomelano-
cortin (POMC) or agouti-related peptide (AgRP) and neuropeptide Y
(NPY) in the arcuate nucleus [41e43]. These ﬁrst order neurons
project to second order neurons in other hypothalamic areas (e.g. the
paraventricular hypothalamus, lateral hypothalamus, and ventrome-
dial hypothalamus) or extrahypothalamic areas (e.g. the nucleus
tractus solitarius) to ultimately alter feeding behavior or energy
metabolism. Insulin decreases expression of orexigenic AgRP and
NPY, leading to decreased food intake [44]. Additionally, insulin in-
creases expression of POMC, resulting in increased levels of a-me-
lanocyte stimulating hormone (a-MSH), which promotes anorexia
and increases energy expenditure [45], presumably via melanocortin-
4-receptors (MC4R) expressing neurons [46]. In AgRP neurons,
once Akt translocates into the nucleus in response to insulin, it
inhibits forkhead box protein O1 (FOXO1) transcriptional activity by
phosphorylating FOXO1, and leads to the exclusion of FOXO1 from the
Table 2 e (continued )
Memory Amnestic MCI or early
AD or healthy
single dose (20 IU or
40 IU)
Verbal memory Facilitated recall on two measures of verbal memory in
memory-impaired APOE- 34- adults. These effects
were stronger for memory-impaired APOE- 34-
subjects than for memory-impaired APOE- 34þ
subjects and normal adults.
[15]
Amnestic MCI or early
AD
3 weeks (20 IU) Verbal memory Enhanced verbal memory, selective attention, and
functional status.
[123]
Raised fasting plasma A beta 40/42 ratio.
Amnestic MCI or AD or
healthy subjects
5 days (10, 20, 40, or
60 IU)
Verbal memory Facilitated recall on two measures of verbal memory in
memory-impaired APOE- 34- adults.
[121]
Differentially modulated plasma amyloid-b for
memory-impaired subjects and normal controls, with
effects that differed by APOE genotype.
Healthy men 8 weeks (40 IU, q.i.d.) Declarative
memory
Improved declarative memory. [122]
Healthy men 8 weeks (40 IU, q.i.d.) Declarative
memory
Improved declarative memory and attention. [119]
Obese men 8 weeks (40 IU, q.i.d.) Declarative
memory
Improved declarative memory. [80]
Amnestic MCI or mild
to moderate AD
4 months (20 or 40 IU) Dementia Improved delayed memory with 20 IU intranasal
insulin.
[124]
Testing Preserved cognition and functional abilities with 20
and 40 IU insulin.
Correlation between effects on memory and function
with CSF Ab42 and tau/Ab42.
APOE- 34 carriers with
mild-moderate AD
Single dose (40 IU) Memory No impact on cognition; serum insulin levels dropped
post treatment, but peripheral glucose levels were
unchanged.
[145]
Healthy men Single dose (40 IU) Memory Improved odor-cued reactivation of spatial memory. [146]
Normal weight men or
women
Single dose (160 IU) Working memory Improved hippocampus-dependent memory and
working memory in women, not men.
[72]
Normal weight pre and
post menopausal
women
Single dose (160 IU) Working memory Enhanced prefrontal cortex-dependent working
memory.
[73]
MCI or mild to
moderate AD
3 weeks (20 or 40 IU) Working memory Improved memory composite (in APOE- 34 carriers),
verbal working memory and visuospatial working
memory with 40 IU of insulin detemir.
[147]
Non-diabetic and
diabetic men and
women
Single dose (40 IU) Visio-spatial
memory
Improved visiospatial memory acutely, correlated with
regional vasoreactivity and cerebral vasodilatation.
[120]
Older adults with type
2 diabetes
Single dose (40 IU) Cognitive
performance
Increased resting-state functional connectivity
between the hippocampal regions and default mode
network.
[148]
Mood Obese men 8 weeks (40 IU, q.i.d.) HPA axis Improved mood and reduces HPA axis activity. [80]
Healthy men Single dose (40 IU) HPA axis Reduced saliva and plasma cortisol after experimental
social stress.
[136]
Healthy men 8 weeks (40 IU, q.i.d.) Mood Enhanced mood and self-conﬁdence, reduces anger. [119]
Bipolar disorder,
euthymic
8 weeks (40 IU, q.i.d.) Executive function Improved executive function, as measured by the Trail
Making Test-Part B.
[137]
No effect on other neurocognitive tests.
AD, Alzheimer’s disease; CNS, central nervous system; CSF, cerebrospinal ﬂuid; FFA, free fatty acid; fMRI, functional magnetic resonance imaging; HOMA-IR, homeostasis model
assessment-insulin resistance, HPA, hypothalamic-pituitary-adrenal; MCI, mild cognitive impairment; t.i.d., ter in die (three times a day); q.i.d., quarter in die (four times a day).
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nucleus resulting in the reduction of AgRP expression [47]. In unsti-
mulated POMC neurons, FOXO1 enhances recruitment of histone
acetylases and co-suppressors on the promoter region of POMC
genes to suppress its expression. Upon insulin stimulation, phos-
phorylated FOXO1 translocates from the nucleus resulting in
de-inhibition of the POMC promoter, thereby increasing POMC
expression [47e49]. Interestingly, regulation of HGP is affected by
hypothalamic insulin signaling [8]. A branched-pathway model sug-
gests that insulin receptor knock-in in POMC neurons promotes HGP
and activates melanocortinergic energy expenditure whereas insulin
receptor knock-in in AgRP neurons decreases HGP [50].
However, in contrast to brain-wide insulin receptor knockout [7] or
disruption of POMC- or AgRP-expressing neurons [51,52], selective
inactivation of the insulin receptor in either POMC- or AgRP-expressing
neurons failed to exhibit altered food intake or body weight, raising the
question of whether insulin action in these neurons is necessary for
energy homeostasis [41]. Because other neuronal populations are
known to regulate energy balance in response to leptin (e.g. ste-
roidogenic factor-1 (SF-1) neurons of the VMH [53,54]), insulin action
in these neuron populations may also contribute to its role in the
central nervous system. A recent study indicated that insulin-
dependent PI3K activation in SF-1 expressing VMH neurons contrib-
uted to diet-induced obesity by reducing ﬁring frequency [55]. Another
potential explanation is that both insulin and leptin signals are required
for normal glucose homeostasis [43] because they stimulate different
populations of POMC-expressing neurons [56].
3.4. Intranasal insulin regulates human glucose homeostasis
The introduction of the intranasal application of insulin provides us with
a tool to evaluate insulin’s role in the human CNS on whole-body
metabolism. From the perspective of insulin’s glucose-lowering ac-
tion, one of the most intriguing questions is whether the administration
of insulin via the intranasal route alters circulating glucose levels in
humans directly or indirectly. Experimental data in humans demon-
strated that intranasal insulin administration led to increased insulin
levels in the CSF but not in the bloodstream and did not induce change
in blood glucose levels [22]. These observations suggested that insulin
directly entered the CSF, bypassing the bloodstream without affecting
circulating insulin and glucose levels. However, some studies revealed
that administration of intranasal insulin increased circulating insulin
levels and decreased glucose levels, although it remained with the
range of euglycemia [57,58]. The difference between these studies
could be due to either the intranasal insulin dose used or the duration
of intranasal insulin therapy.
Several studies examined the effect of intranasal insulin treatment on
glucose homeostasis in normal and type 1 or type 2 diabetic patients
(Table 2). Reduction in glucose levels was observed by a single or
multiple administrations with various doses [27,57,59e66], while
some studies failed to demonstrate this effect [67e70]. Given that
one of insulin’s actions in the hypothalamus is to regulate HGP [38], it
is conceivable that brain insulin in humans plays a role in regulating
systemic blood glucose levels through the brain-liver axis. It has also
been suggested that CNS insulin exerts a positive feedback on the
pancreas to increase insulin secretion [34]. Of note, a recent study
demonstrated that intranasal-induced insulin delivery in the brain
improves peripheral insulin sensitivity by increasing hypothalamic
activity and parasympathetic output in lean men [71]. Further studies
will be needed to elucidate the mechanism of intranasal insulin’s
action and to ﬁnd an efﬁcient way to deliver insulin leading to
favorable outcomes. In addition, because previous studies used
different amounts of or delivery schemes for insulin application which
might have affected the conﬂicting results, investigating the optimal
dose, frequency and duration of intranasal insulin treatment will be
crucial.
3.5. Intranasal insulin regulates brain activity to modulate human
energy homeostasis
Extensive studies have been conducted to identify the impact of
intranasal insulin administration on energy homeostasis. In normal
weight adults, intranasal insulin (160 IU) acutely decreased food
intake in men, however body weight was not altered under these
conditions in pre or post menopausal women [72,73]. Similar results
were observed in subjects receiving long-term intranasal insulin (40
IU, four times a day [q.i.d.], for 8 weeks) [74]. Nevertheless, post-
prandial administration of intranasal insulin (160 IU) was found to
attenuate appetite, food intake and food palatability in women [75]. In
healthy men, intranasal insulin (160 IU) acutely increased postprandial
energy expenditure and decreased circulating insulin [75]. Functional
magnetic resonance imaging (fMRI) studies have begun to reveal the
insulin-mediated changes in activity in the human brain related to
food intake. In normal weight men, intranasal insulin (40 IU) increased
brain ATP and phosphocreatine, and changes in brain energy content
were inversely proportional to subsequent caloric intake, suggesting
that intranasal insulin may play a role in meal termination [76]. In
normal weight adults, intranasal insulin acutely reduced food image-
cued activity in the left and right fusiform gyrus, right hippocampus,
and right temporal superior and frontal middle cortices, areas involved
in object processing and memory. Of note, insulin did not affect
nonfood image-cued brain activity [77]. Lastly, in normal weight
women, intranasal insulin (160 IU) acutely modulated hypothalamic
and orbitofrontal cortex activity, and the prefrontal cortex and anterior
cingulate cortex’s insulin response correlated with body mass index
[78].
Few studies have examined the effects of intranasal insulin on body
weight in patients with obesity, diabetes, or metabolic syndrome. One
day 160 IU of intranasal insulin reduced cerebral blood ﬂow in the
prefrontal cortex in lean participants, but not in overweight/obese
participants, suggesting impaired brain insulin action in the latter
group. Furthermore, behavioral changes for craving sweet foods were
not observed in the overweight/obese group [79]. In obese men, long-
term intranasal insulin (40 IU q.i.d., for 8 weeks) did not reduce body
weight or body fat, unlike in lean men, suggesting that in obesity,
pathways or brain areas that mediate the effects of insulin on body
weight are resistant to the effects of insulin [80]. Taken together,
these studies support an important role for insulin in the CNS in
regulating energy balance. Further studies are needed to determine
whether the effect of intranasal insulin to reduce body adiposity in
obesity is limited.
4. CNS INSULIN ACTION, MEMORY AND COGNITIVE FUNCTION
Interest in the effects of insulin on cognition date to the 1920e30’s
with the advent of Insulinshockbehandlung in Europe [81]. Originally
tested as a methodology to change the mental status of patients with
delirium tremens or morphine addiction, insulin shock therapy or
insulin coma therapy was advanced by Manfred Sakel as a treatment
for psychosis in dementia praecox (or premature dementia, a diag-
nosis that today would most closely refer to schizophrenia), and later
occasionally in depressive disorders [81e83]. While insulin shock
therapy was largely abandoned in the 1950’s consequent to the
emergence of antipsychotic medications and a lack of evidence that
insulin was the therapeutic component of coma therapy [81,84], it
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ushered in an era of studies of the effects of insulin on learning and
memory, originally stemming from the mistaken belief that insulin
shock therapy promoted the unlearning of newly acquired psychotic
behaviors [85]. Despite its inauspicious beginning, interest in the
role of the hormone insulin in the CNS on cognitive and affective
disorders has persisted, with renewed interest in the initial years of
this century.
4.1. Is dementia a metabolic disorder?
Besides regulating neural circuits involved in maintaining energy
homeostasis, insulin also inﬂuences cognitive functions through its
actions on synaptic plasticity and long-term potentiation in the hip-
pocampus and other brain regions involved in learning and memory
[86,87]. Recent studies also have indicated a strong association be-
tween Alzheimer’s disease and CNS insulin resistance [88,89]. Alz-
heimer’s disease is a neurodegenerative disease causing progressive
deterioration of memory and cognitive function and is the most
common form of dementia, accounting for more than 50% of cases
[90]. Although aging is the most prominent risk factor, now there is
ample evidence that people with glucose intolerance, insulin resis-
tance and metabolic syndrome are at higher risk for cognitive
impairment and dementia compared to age- and gender-matched
controls [91e94]. A meta-analysis and a large-scaled pooled anal-
ysis demonstrate that diabetes is associated with an approximately
60e70% increased risk of all types of dementia [95,96]. Therefore,
Alzheimer’s disease is sometimes referred as type 3 diabetes, a brain
speciﬁc impairment of insulin signaling [89]. Multifactorial patho-
geneses that can be linked to brain insulin signaling defects, such as
oxidative stress due to hyperglycemic toxicity, chronic inﬂammatory
processes, mitochondrial dysfunction, abnormal cholesterol meta-
bolism, adverse vascular changes and severe hypoglycemia are
thought to trigger the development of dementia in people with
metabolic disturbances (reviewed in [97,98]).
4.2. Brain insulin resistance is implicated in memory impairment
and cognitive dysfunction
Insulin resistance was associated with progressive atrophy in cortical
regions affected by Alzheimer’s disease, and this corresponded to
worse cognitive performance in asymptomatic, late middle-aged
adults [99]. Dysregulation of brain insulin signaling has been pro-
posed as a causal mechanism. A recent study highlighted that serine
phosphorylation of IRS1 is a common pathophysiologic mechanism of
Alzheimer’s disease and diabetes. The levels of IRS1 serine phos-
phorylation and their activated kinases showed a positive correlation
with levels of oligomeric b-amyloid (Ab) plaques and an inverse as-
sociation with memory and cognition [100]. A study using autopsied
frontal cortices showed that the expression levels of several compo-
nents of the insulin-PI3K-Akt signaling pathway were decreased in
subjects with type 2 diabetes and/or Alzheimer’s disease [101]. Similar
ﬁndings were also observed in a rat model of sporadic Alzheimer’s
disease [102]. This was associated with an over-activation of glycogen
synthase kinase-3b (GSK-3b), which in turn hyperphosphorylates
microtubule-associated protein tau, a major component of neuroﬁ-
brillary tangles that disrupt neuronal function [101e103]. GSK-3b is
regarded as the key signaling molecule regulating tau phosphorylation,
and its activity is negatively regulated by its phosphorylation with Akt at
Ser9. In addition to hyperphosphorylation, tau can also undergo
O-GlcNAcylation, a post-translational protein modiﬁcation by O-linked
N-acetyl-D-glucosamine (O-GlcNAc). Because this modiﬁcation is
regulated by glucose availability via the hexosamine biosynthesis
pathway, downregulation of O-GlcNAcylation by impaired brain glucose
metabolism facilitates tau hyperphosphorylation [104]. Conversely, an
O-GlcNAcase inhibitor increased tau O-GlcNAc which correlates with
decreased tau aggregates and neuronal cell death [105]. Therefore,
brain insulin resistance is now considered as a causal factor of
neuroﬁbrillary degeneration.
Of note, Alzheimer’s disease itself can induce or augment insulin
resistance, thus participating in type 2 diabetes pathogenesis or other
metabolic dysfunctions. Ab oligomers stimulate tumor necrosis factor
(TNF)-a signaling, which activates the c-Jun N-terminal kinase (JNK)
pathway resulting in serine phosphorylation of IRS1 and defective in-
sulin signaling [106]. Ab oligomers also induced substantial loss of
neuronal surface insulin receptors and inhibited neuronal response to
insulin, which was associated with Akt phosphorylation at Ser473, in
hippocampal neurons [88]. These ﬁndings suggest that the link be-
tween insulin resistance and Alzheimer’s disease could be
bidirectional.
4.3. Diet and diabetes alter CNS insulin action and cognitive
function in animals
Diet may play an important part in the development of insulin resis-
tance in the brain. In hamsters, a diet high in fructose induces pe-
ripheral as well as neural insulin resistance, as evidenced by
decreased insulin-mediated IR, IRS1, and Akt phosphorylation and
elevated protein-tyrosine phosphatase 1B (PTP1B) expression in the
cerebral cortex and hippocampus [107]. Insulin-induced long-term
depression, a functional measure of synaptic plasticity, was also
attenuated in the brains of these animals, suggesting that brain insulin
resistance may contribute to cognitive impairment [107]. High fat
feeding of rats also impaired neuronal insulin signaling and long-term
depression in the CA1 region of the hippocampus [108]. Rosiglitazone,
an insulin sensitizer, reversed high-fat diet-induced neuronal insulin
resistance and associated impairments in insulin-induced long-term
depression and increased neuronal Akt serine phosphorylation in
response to insulin [109]. Treatment of high-fat fed mice with vilda-
gliptin, a dipeptidyl peptidase-4 inhibitor (anti-diabetic drug), also
restored insulin-induced neuronal IR, IRS1, and Akt activation and
long-term depression, improved brain mitochondrial dysfunction, and
enhanced cognitive function measured by the Morris water maze test
[110]. Furthermore, insulin treatment rescued impaired hippocampal
neuron proliferation in mice with experimental diabetes [111]. Taken
together, insulin’s action in the CNS is crucial in maintaining cognitive
function in animals.
4.4. Insulin’s role in learning, memory, and cognition: animal
studies
Diet-induced impaired neural insulin signaling in animal models of
Alzheimer’s disease-like neuropathology promoted amyloidogenic
Ab1e40 and Ab1e42 peptide generation, increased Alzheimer’s
disease-type amyloid plaque burden in the brain and impaired per-
formance in a spatial water maze task [112]. Ab is implicated in
initiating a deterioration of synapse function, composition, structure,
and plasticity in Alzheimer’s disease. In hippocampal neuron cultures,
Ab causes loss of IR on dendrites and interferes with insulin receptor
signaling and long term potentiation [88,113]. In brain/neuron-
speciﬁc insulin receptor knockout (NIRKO) mice, neuronal prolifera-
tion, neuronal survival, basal brain glucose metabolism or memory
was not altered [114]. Neuronal-speciﬁc insulin receptor deletion also
did not affect lethality of mice expressing the Swedish mutation of the
amyloid precursor protein (APPSW), a model for Alzheimer’s disease
[115]. However, in NIRKO mice, Akt and GSK3b phosphorylation was
markedly reduced, tau phosphorylation substantially increased, and
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insulin-stimulated PI3-kinase activation and neuronal apoptosis were
blocked or inhibited, respectively, raising the possibility that insulin
receptor deﬁciency in the brain may inﬂuence the risk of developing
Alzheimer’s disease independent of neuronal apoptosis or survival
[114]. Moreover, intranasal insulin administration in mice improved
short- and long-term object memory recognition [116]. Of note, the
effects of intranasal insulin on memory were blunted by diet-induced
obesity [116]. Similarly, mice heterozygous for the insulin receptor
gene demonstrated poor performance on both short-term (1 h) and
long-term (24 h) memory tests in comparison to that of wild-type mice
[117]. Impaired brain insulin signaling and tau hyperphosphorylation
in a rat model of type 2 diabetes were normalized by intranasal insulin
[118]. Experimental research suggesting that insulin plays an
important role in memory are further supported by clinical studies
examining the impact of intranasal insulin on memory in healthy
subjects as well as patients with diabetes, amnesic mild cognitive
impairment, or Alzheimer’s disease.
4.5. Intranasal insulin regulates brain activities involved in learning
and memory in human
Besides its effect on peripheral energy metabolism, intranasal insulin
has been proposed as a novel therapy to improve memory and
cognition in humans. Several studies involving both healthy and
cognitively impaired subjects have evaluated the effect of intranasal
insulin on cognitive function (Table 2). Although variable results were
observed according to the dose of insulin (160 IU vs. lower dose),
duration of treatment (acute vs. long-term), timing of assessment
(immediate recall vs. delayed recall), measures of cognitive function
(word list recall, digit span or object recognition) and gender, potential
beneﬁcial effects were suggested. Numerous studies demonstrated
improvement in memory or cognitive functions after the administration
of intranasal insulin, with the effect being more prominent in women
than in men [15,72,73,80,119e122]. These data suggest that intra-
nasal insulin has the potential to enhance working memory perfor-
mance even in healthy non-diabetic subjects.
In subjects with amnestic mild cognitive impairment or probable Alz-
heimer’s disease, acute administration of 20 IU insulin improved im-
mediate and delayed verbal memory [123]. Another clinical trial
evaluated the effect of a 4-month treatment of 20 IU or 40 IU intranasal
insulin in adults with amnestic mild cognitive impairment or Alz-
heimer’s disease. Memory and recall tasks were markedly improved
with 20 IU of insulin, and general cognition and functional abilities were
preserved with both doses of insulin [124]. Studies by Reger et al.
showed that the effect on verbal memory was greater in participants
without the APOE-epsilon4 allele, a risk factor for Alzheimer’s disease,
suggesting a differential dose-response reaction of intranasal insulin in
groups with different genetic backgrounds [15,121]. These results,
along with an excellent safety proﬁle and compliance, provide the basis
for future clinical trials to establish a new role of insulin for the
treatment of dementia.
5. CNS INSULIN ACTION AND MOOD
5.1. Depression is a common co-morbidity of diabetes and
involves abnormalities in insulin action
“In our work with diabetic children, we have always been impressed with
the marked symptoms of depression shown by these patients. We have
observed that the most noticeable reaction from the use of insulin was the
clearing of the depression. This observation led us to make some
investigations into the possible effect of insulin in states of true mental
depression.” (Cowie DM, et al., 1924) [125]
Recognition of an association between diabetes and depression
predates the modern diagnostic conceptualization for either disorder.
Indeed, the British physician Thomas Willis, who was one of the ﬁrst to
recognize glycosuria as a symptom of diabetes, postulated that dia-
betes was caused by ‘sadness or long sorrow and other depressions
and disorders’ [126]. Major depressive disorder (MDD) is a common
co-morbidity of diabetes [126,127], although the biological basis of
MDD is not clearly understood. Evidence suggests that the relation-
ship between MDD and diabetes is bidirectional [127,128]. Insulin
resistance, hypothalamic-pituitary-adrenal (HPA) axis dysregulation,
and inﬂammation have been implicated as mechanistic links between
the two disorders [128]. As in diabetes [129] and dementia [130],
cerebral glucose metabolism is markedly altered in MDD [131].
Moreover, systemic insulin resistance has been described as a
pathogenic feature of MDD [128]. Indeed, in a recent plasma prote-
omics study aimed at identifying peripheral markers of MDD, the
analyte with the greatest differential expression and statistical sig-
niﬁcance between healthy and MDD subjects was insulin [132].
Moreover, emerging experimental and clinical data suggest that in-
sulin action in brain may play a direct role in controlling mood
regulation and cognition in MDD.
5.2. Brain insulin signaling is involved in depression-like states in
animals
Recent studies in animals lend support to the concept that insulin
action in the CNS has important effects on mood. High fat feeding of
rats elevates neuronal corticosterone and impairs neuronal insulin
signaling and long-term depression in the CA1 region of the hippo-
campus, indicating pathophysiological links between metabolic
overload, neuronal stress and neuronal insulin resistance [108]. In
rats exposed to chronic unpredictable mild stress (CUMS) to induce a
depression-like state, insulin-stimulated IRS2 tyrosine phosphoryla-
tion and PI3K activation are suppressed, and suppressor of cytokine
signaling 3 (SOCS3) is overexpressed in the arcuate nucleus of the
hypothalamus. These effects were reversible by treatment with the
antidepressant ﬂuoxetine [133]. Moreover, in rats, lentivirus-mediated
hypothalamic insulin receptor-knockdown promoted anhedonia and
behavioral despair, as measured by the sucrose preference test and
forced swim test, respectively [134]. Furthermore, pretreatment of
mice with the insulin sensitizer dicholine succinate prior to social
defeat stress diminished anhedonia and behavioral despair. Dicholine
succinate pretreatment also reduced the anxiety scores of stressed
mice in the dark/light box paradigm and blocked stress-induced
impairments of long-term contextual memory in the step-down
avoidance test, while preserving hippocampal gene expression of
insulin-like growth factor 2 [135]. NIRKO mice also develop age-
related anxiety and depression-like behaviors accompanied by cen-
tral mitochondrial dysfunction, increased oxidative stress, and
increased lipid and protein oxidation in the striatum and nucleus
accumbens [10]. Insulin receptor deﬁciency increases brain mono-
amine oxidase (MAO) A and B in these brain regions, leading to an
increase in dopamine turnover. The depression-like behaviors NIRKO
mice exhibit are reversible via treatment with MAO inhibitors and
other antidepressants [10]. Collectively, these data support the idea
that impairments in CNS insulin receptor signaling may contribute to
depression-like behaviors in animals. Further clinical studies are
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needed to determine whether impaired CNS insulin action contributes
to mood dysregulation in MDD.
5.3. Intranasal insulin treatment improves mood and attenuates
HPA axis hyperactivity in clinical studies
In healthy subjects, administration of intranasal insulin (40 IU) prior to a
psychosocial stressor was found to diminish saliva and plasma cortisol
without affecting heart rate or blood pressure stress reactivity, sug-
gesting that intranasal insulin blunts the responsiveness of the stress-
induced HPA axis [136]. Longer-term treatment with intranasal insulin
(eight weeks, 40 IU, q.i.d.) not only improved declarative memory and
attention, but also enhanced mood and self-conﬁdence, and reduced
anger in healthy subjects [119]. Importantly, although obese subjects
were resistant to the effects of longer-term intranasal insulin (eight
weeks, 40 IU, q.i.d.) to reduce weight or adiposity, they remained
sensitive to insulin’s effects to improve declarative memory and mood
[80]. Of note, intranasal insulin therapy also acutely and chronically
lowered plasma adrenocorticotropic hormone (ACTH) and serum
cortisol in obese subjects, suggesting that HPA axis activity was
reduced [80]. The potential impact of intranasal insulin on mood in
patients with depression has not yet been investigated. However, in an
initial study of euthymic bipolar disorder patients, adjunctive intranasal
insulin treatment (eight weeks, 40 IU q.i.d.) improved one measure of
executive function [137]. Collectively, these studies suggest that in-
sulin action in the brain may be an important component of the
neuroendocrinology of mood regulation, in part via blunting hyperac-
tivity of the HPA axis. Further clinical studies are needed to determine
whether intranasal insulin or insulin sensitizers may have the potential
to normalize mood and HPA axis activity in affective disorders and treat
MDD.
6. CONCLUSIONS
The ﬁeld of metabolic physiology has been greatly advanced by the
elucidation of insulin’s function in the brain regulating systemic energy
metabolism, memory, and mood. Over the past decade, extensive
research has shed light on a new role of insulin in CNS-related
metabolic disorders, including dementia, memory impairment, and
cognitive dysfunction. In addition, accumulating evidence demon-
strates that intranasal insulin administration represents a potential
treatment option for these conditions. However, knowledge on this
area needs to be further advanced in order to understand the precise
role of insulin in the brain, and its effect on metabolic and neurode-
generative diseases. Because assessing brain insulin resistance is still
technically limited, development of better measures or technology to
identify the action of brain insulin would be important. Furthermore,
large-scale clinical trials for pharmacological treatments, including
intranasal insulin, that promote brain insulin sensitivity may provide
novel therapeutic possibilities for the treatment of cognitive and mood
disorders in the future.
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